Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05914116 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of DB-1311 in Advanced/Metastatic Solid Tumors

Start date: September 5, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311 in subjects with advanced solid tumors.

NCT ID: NCT05912062 Recruiting - Breast Cancer Clinical Trials

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

BiOnHER
Start date: March 22, 2021
Phase:
Study type: Observational

Non-randomized, open label, translational research study in women with early HER2-positive invasive breast carcinoma eligible for neoadjuvant treatment. The aim of BIONHER is to assess the impact of short-term neoadjuvant dual HER2-blockade on HER2-positive breast cancer transcriptomic profile and to evaluate whether early on treatment tumor biopsy can improve the accuracy of predicting response over the pre-treatment alone.

NCT ID: NCT05911464 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.

NCT ID: NCT05909436 Recruiting - Solid Tumor Clinical Trials

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Start date: October 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.

NCT ID: NCT05909241 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of BA1202 in Patients With Advanced Solid Tumors

Start date: August 16, 2023
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, single-arm phase I study in patients with advanced solid tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B). Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B will also evaluate the preliminary efficacy of BA1202.

NCT ID: NCT05907980 Recruiting - Solid Tumor Clinical Trials

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

Start date: May 24, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

NCT ID: NCT05907603 Recruiting - Neoplasms Clinical Trials

Research Development(RD)13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7(CD7)+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

Start date: March 8, 2023
Phase: Early Phase 1
Study type: Interventional

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the pharmacokinetics of CD7 CAR-T in patients.

NCT ID: NCT05907551 Recruiting - Neoplasms Clinical Trials

Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions

DERMOCOS
Start date: July 25, 2023
Phase:
Study type: Observational

Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities. When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and individual susceptibility. Although these dermatological adverse events are rarely serious, they can significantly alter patients' quality of life, and may even necessitate the introduction of curative treatment. The impact of these side effects can be mitigated by the use of dermo-cosmetic products and aesthetic solutions. However, most of this supportive care is not reimbursed by the health insurance system, representing a source of inequalities in access to healthcare for cancer patients.

NCT ID: NCT05906862 Recruiting - Clinical trials for Advanced Solid Tumor

AMT-253 in Patients With Selected Advanced Solid Tumours

Start date: November 6, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors

NCT ID: NCT05904457 Recruiting - Solid Tumors Clinical Trials

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer

BRISK
Start date: January 2, 2023
Phase: Phase 2
Study type: Interventional

A national, prospective, multi-center, open-label, single arm phase II trial investigating the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which harbors genomic alterations in Krebs cycle